COMP <GO>
TRSG vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Tungray Technologies Inc (Class A) (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TRSG 1
— TMO 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $1.18 (+0.69%) • MKT CAP: $19.2M
roic
-1.70%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRSG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRSG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -1.70% | 9.30% | -11.00 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.00% | 2.40% | -22.40 | TMO | /fcf-yield <GO> |
| Operating Margin | -1.50% | 17.40% | -18.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | -1.10% | 15.10% | -16.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 3.90% | +18.10 | TRSG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.59 | 4.50 | -1.91 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.0 | 62.9 | -19.87 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $19.2M | $262.22B | -$262.20B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRSG REV | TMO REV | TRSG GROSS % | TMO GROSS % | TRSG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $15.6M | $44.56B | 45.9% | — | -$3.8M | $6.29B |
| FY 2024 | $12.8M | $42.88B | 43.7% | — | -$1.3M | $7.27B |
| FY 2023 | $14.4M | $42.86B | — | — | $451.0K | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRSG // BETA —
TMO // BETA 0.94